Kiniksa (KNSA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Risks for Kiniksa Pharmaceuticals (KNSA) are limited to standard laboratory waste controls. The EV/EBITDA trajectory demonstrates a support level where the metric stands at 53.26. Stability is driven by the outsourced production of Arcalyst and high sales margins. Efficiency is further enhanced by the direct-to-patient delivery of rare disease medications, which minimizes costs and ensures the integrity of high-value shipments.
kiniksa.com - analytical breakdowns and key metrics (KNSA)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
KNSA - Company Profit|Projected Future Earnings Kiniksa Pharmaceuticals|KNSA - Business Payback Period|Future Price to Earnings Kiniksa Pharmaceuticals|KNSA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kiniksa Corp|KNSA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Kiniksa|KNSA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months kiniksa.com|KNSA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Kiniksa Pharmaceuticals
- sales and revenue data:
Initial company analysis:KNSA (Kiniksa Pharmaceuticals Ltd)
Comparative asset analysis requires evaluating business value relative to its operating profit before depreciation, taxes, and interest. The EV/EBITDA multiple for Kiniksa Pharmaceuticals (KNSA), accounting for debt load, compares market capitalization and debt against actual cash flow, which is critical for the biotech sector given its massive R&D expenditures. The patent protection of antibodies held by Kiniksa Pharmaceuticals ensures a monopoly, justifying the current market value as reflected in this chart.
Competitors of Kiniksa Pharmaceuticals
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio GRFS|EV/EBITDA Multiple Adaptive Biotechnologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celldex Therapeutics (CLDX)|auriniapharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Company Value to EBITDA|DNTH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHVS - EV/EBITDA Multiple|ABCL: EV/EBITDA Multiple|TRML - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precigen|Enterprise Value to Operating Income Before Depreciation PHAR (Pharming Group NV)|EV/EBITDA Multiple NKTR|Total Company Value to Operating Income Before Depreciation Ratio Upstream Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zenas Biopharma Inc ZBIO|EV/EBITDA Multiple immunome.com IMNM|GOSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio KalVista Pharma KALV|SEPN: EV/EBITDA Multiple|Pieris Corp (PVLA) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio SVRA|RIGL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AnaptysBio (ANAB)|ATXS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ENGN (enGene Bio)|Business Value to Operating Income Before Depreciation RAPT|Aerovate - EV/EBITDA Multiple|ACRS - EV/EBITDA Multiple|Kyverna Therapeutics, Inc. (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Tiziana Life Sciences Ltd. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio, Inc|Enterprise Value to EBITDA Ratio Ventyx Biosciences, Inc (VTYX)|EV/EBITDA Multiple THTX|EV/EBITDA Multiple avalotx.com (AVTX)|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|AGEN - Enterprise Value to EBITDA Ratio|Climb Bio, Inc. - EV/EBITDA Multiple|Company Value to EBITDA zurabio.com|ATYR (aTyr Pharma, Inc.) - Enterprise Value to EBITDA Ratio|Adagene Inc. (ADAG) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio IMA|STTK (Shattuck Therapeutics) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|EV/EBITDA Multiple IMUX (Immunic)|ATRA - Enterprise Value to EBITDA Ratio|InflaRx GmbH - EV/EBITDA Multiple|XFOR - EV/EBITDA Multiple|adicetbio.com (ACET) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELU (Celularity) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|barinthusbio.com (BRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc. (KZR)|EV/EBITDA Multiple SAB Biotherapeutics Inc. (SABS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|ENLV: Enterprise Value to Operating Income Before Depreciation|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio geovax.com GOVX|EDSA: EV/EBITDA Multiple|iBio Inc (IBIO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Carisma Therapeutics Inc|XTL Bio - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BOLT|HCWB (hcwbiologics.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|EV/EBITDA Multiple aimimmuno.com AIM|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GRI (GRI Bio Corporation)|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Indaptus Therapeutics Inc|Enterprise Value to EBITDA Ratio SCNI (Scinai)|CALI (calcimedica.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple AFMD (Affimed N.V.)|Total Company Value to Operating Income Before Depreciation Ratio Allakos Inc (ALLK)|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Ocean Biomedical Corp|Enterprise Value to EBITDA Ratio TCBP|EV/EBITDA Multiple thirdharmonicbio.com
